Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA.
Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA.
J Chromatogr A. 2014 Jan 31;1327:105-17. doi: 10.1016/j.chroma.2013.12.067. Epub 2013 Dec 30.
Clandestine laboratories constantly produce new synthetic cannabinoids to circumvent legislative efforts, complicating toxicological analysis. No extensive synthetic cannabinoid quantitative urinary methods are reported in the literature. We developed and validated a liquid chromatography-tandem mass spectrometric (LC-MS/MS) method for simultaneously quantifying JWH-018, JWH-019, JWH-073, JWH-081, JWH-122, JWH-200, JWH-210, JWH-250, JWH-398, RCS-4, AM-2201, MAM-2201, UR-144, CP 47,497-C7, CP 47,497-C8 and their metabolites, and JWH-203, AM-694, RCS-8, XLR-11 and HU-210 parent compounds in urine. Non-chromatographically resolved alkyl hydroxy metabolite isomers were considered semi-quantitative. β-Glucuronidase hydrolyzed urine was extracted with 1ml Biotage SLE+ columns. Specimens were reconstituted in 150μL mobile phase consisting of 50% A (0.01% formic acid in water) and 50% B (0.01% formic acid in 50:50 methanol:acetonitrile). 4 and 25μL injections were performed to acquire data in positive and negative ionization modes, respectively. The LC-MS/MS instrument consisted of a Shimadzu UFLCxr system and an ABSciex 5500 Qtrap mass spectrometer with an electrospray source. Gradient chromatographic separation was achieved utilizing a Restek Ultra Biphenyl column with a 0.5ml/min flow rate and an overall run time of 19.5 and 11.4min for positive and negative mode methods, respectively. Quantification was by multiple reaction monitoring with CP 47,497 compounds and HU-210 ionized via negative polarity; all other analytes were acquired in positive mode. Lower and upper limits of linearity were 0.1-1.0 and 50-100μg/l (r(2)>0.994). Validation parameters were evaluated at three concentrations spanning linear dynamic ranges. Inter-day analytical recovery (bias) and imprecision (N=20) were 88.3-112.2% and 4.3-13.5% coefficient of variation, respectively. Extraction efficiencies and matrix effect (N=10) were 44-110 and -73 to 52%, respectively. We present a novel LC-MS/MS method for simultaneously quantifying 20 synthetic cannabinoids and 21 metabolites, and semi-quantifying 12 alkyl hydroxy metabolites in urine.
隐蔽实验室不断生产新的合成大麻素以规避立法努力,使毒理学分析变得复杂。文献中没有报道广泛的合成大麻素定量尿方法。我们开发并验证了一种液相色谱-串联质谱(LC-MS/MS)方法,用于同时定量 JWH-018、JWH-019、JWH-073、JWH-081、JWH-122、JWH-200、JWH-210、JWH-250、JWH-398、RCS-4、AM-2201、MAM-2201、UR-144、CP 47,497-C7、CP 47,497-C8 和它们的代谢物,以及尿液中的 JWH-203、AM-694、RCS-8、XLR-11 和 HU-210 母体化合物。非色谱分离的烷基羟化物异构体被认为是半定量的。β-葡萄糖醛酸酶水解尿液后用 1ml Biotage SLE+ 柱提取。样品在由 50% A(水中 0.01% 甲酸)和 50% B(50:50 甲醇:乙腈中的 0.01% 甲酸)组成的 150μL 流动相中重新配制。分别以 4μL 和 25μL 进样,在正离子和负离子模式下采集数据。LC-MS/MS 仪器由 Shimadzu UFLCxr 系统和 ABSciex 5500 Qtrap 质谱仪与电喷雾源组成。使用 Restek Ultra Biphenyl 柱以 0.5ml/min 的流速实现梯度色谱分离,正离子和负离子模式的总运行时间分别为 19.5 和 11.4min。通过 CP 47,497 化合物和 HU-210 通过负极性离子化的多反应监测进行定量;所有其他分析物均以正离子模式获得。线性范围的下限和上限分别为 0.1-1.0 和 50-100μg/l(r(2)>0.994)。在三个跨越线性动态范围的浓度下评估验证参数。日间分析回收率(偏差)和精密度(N=20)分别为 88.3-112.2%和 4.3-13.5%变异系数。提取效率和基质效应(N=10)分别为 44-110%和-73 至 52%。我们提出了一种新的 LC-MS/MS 方法,用于同时定量尿液中的 20 种合成大麻素和 21 种代谢物,并对半定量 12 种烷基羟化物代谢物。